According to a new report from Research
and Markets, the global point-of-care (POC) diagnostics market will grow at a compound annual growth rate (CAGR) of 9.3 percent to 2018
Company reports promising preclinical results for its CD70 technology, which may provide
a robust method to expand tumor-specific T cells with improved quality
In Vitro ADMET
Laboratories LLC (IVAL) and Taconic announced an agreement in late March under which IVAL will prepare cryopreserved hepatocytes derived from Taconic’s
knockout and genetically humanized mouse models for use in preclinical drug development research
According to research coming out of the the University of Texas Health Science Center (UTHealth) Medical School at Houston, a Japanese mushroom extract called active hexose correlated compound (AHCC) may have a role in prevention of human papillomavirus (HPV)-related cancers.
Mass spectrometry (MS) technology has advanced extremely rapidly over the last decade, with MS
techniques now being widely used in life science research, and even finding their way into the clinical setting for diagnostic applications. As one of the
first sectors to adopt MS technology, the drug discovery market has been at the forefront of this revolution and, as such, has now become one of the first
areas of research to run up against the major limitation of the technique—sample preparation.
Taking a slight detour from the world of pharma and
biotech, DDNews columnist Peter T. Kissinger lays out his plan to win the war on poverty that was ushered in during the 1960s and has struggled ever since.
It's easy to pick on the pharma and biotech companies and paint them as heartless, money-grubbing opportunists. But the truth is a
bit more complex, and both the public and government need to update the way they look at things.
Alzheimer’s disease and schizophrenia are not often linked in the same sentence, much
less in the same scientific conversation, but in an interview with DDNews, Dr. Deborah Dunsire, president and CEO of Forum Pharmaceuticals, and her colleague
Dr. Lon S. Schneider at USC tell us why perhaps they should be
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.